An open-label clinical trial of oral transmucosal haloperidol and oral transmucosal olanzapine in the treatment of terminal delirium at home

BACKGROUND: The phenomenon of restlessness, agitation, or cognitive disturbances experienced by dying patients is well-known in palliative care; more than half of these patients will experience delirium symptoms at end-of-life. When not identified early and effectively managed, delirium symptoms cou...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyu, Xiao-Juan, Kan, Adrian David, Chong, Poh-Heng, Lin, Keegan, Koh, Yung-Hua, Yeo, Zhi-Zheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011988/
https://www.ncbi.nlm.nih.gov/pubmed/35422053
http://dx.doi.org/10.1186/s13063-022-06238-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011988/
https://www.ncbi.nlm.nih.gov/pubmed/35422053
http://dx.doi.org/10.1186/s13063-022-06238-4

Ejemplares similares